
Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the ...
ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative1 solid tumors at the recommended Phase 2 dose (RP2D) 37% cORR observed in patients with …